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Summary 
One of the causes of variations in the expressed human T cell receptor (TCR) BV (V~) repertoire 
is genetic variation in the germline DNA. Herein evidence is provided that allelic polymorphism 
may affect recombination frequency for a specific V  gene.  Two alleles of the TCR BV3 differ 
only at a single nucleotide position (C/T) within the 23-bp spacer region of the recombination 
signal sequence. These alleles are associated with variable percentages of BV3 cells in the peripheral 
blood, as shown in families and in unrelated normal donors. Individuals homozygous for allele 
2 have  a mean of 8.1%  BV3 cells,  heterozygous individuals  have  a mean of 4.7%  BV3 cells, 
and homozygotes for allele  1 have a mean of 1.2% BV3 cells in CD3 § CD4 + peripheral blood 
T cells. Since the correlation is tight in unrelated individuals and other genetic differences were 
not found in the vicinity of BV3,  we suggest  that  the spacer region  sequence itself modifies 
recombination efficiency. This allelic system provides an example of a novel mechanism by which 
c/s-acting genetic elements may affect recombination  in a natural  in vivo system. 
T 
he vast diversity of TCR and immunoglobulins is created 
primarily by V(D)J recombination in maturing lympho- 
cytes. As a result of this theoretically random process, a reper- 
toire of highly diverse TCR is generated (1), but the observed 
repertoire in mature lymphocytes is skewed because of both 
genetic and environmental factors. Genetic control of the TCR 
repertoire is apparent because of highly similar profiles of TCR, 
Vot and V~ usage among monozygotic twins as opposed to 
unrelated individuals  (2-6).  Genes that influence the TCR 
repertoire include the MHC (2) and the TCR genes them- 
selves. MHC genes mold the TCR repertoire because of rec- 
ognition of peptide Ag in the context of MHC molecules. 
Thus, certain T  cell subsets may be positively or negatively 
selected in the context of one MHC allele but not another. 
TCIL V gene segments are deleted in certain mouse haplo- 
types (7). Genomic deletions in the TCRBV locus also exist 
in humans (8) and directly affect the number of genomic V 
gene segments (9). In addition, a number of aUelic polymor- 
phisms of TCR V gene exons have been described. Some of 
these result in null alleles (10, 11) and others result in different 
amino acid sequences at putative Ag/MHC or SAG-reactive 
sites (12-15). It is also possible that TCR gene elements fail 
to rearrange  efficiently because of structural  constraints  on 
some aspect of the recombinase machinery. 
This report describes a new type of polymorphism  that 
can shape the TCR repertoire.  AUelic variation in the TCRBV3 
recombination signal sequence (R.SS) is associated with the 
level of BV3 gene segment utilization in the peripheral blood 
(formerly V~3, the new WHO-IUSIS recommended nomen- 
clature  is  used  throughout  this  manuscript.  Bull.  WHO 
71:113-115, 1993). Variable expression of BV3 was first mapped 
to the TCRB locus in family studies and then shown to corre- 
late with allelic  variants of the BV3 RSS in unrelated indi- 
viduals,  which suggests a direct role for the RSS in deter- 
mining  the frequency with  which  the BV3 gene segment 
undergoes V-DJ recombination. It is surprising that the single 
point mutation is located in the nonconserved spacer region 
of the P,  SS. This allelic system demonstrates a novel mecha- 
nism whereby genetic factors affecting recombination  may 
strongly skew expression of certain  gene segments. 
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Donors.  The unrelated  donors are normal adults of  various  ethnic 
backgrounds. The families include the D family (Irish), 98, 110, 
and 23 families, all of northern European ancestry. 
Immunofluorescence.  Indirect two-  and single-color immuno- 
fluorescence was performed as described elsewhere (16) using the 
anti-TCR mAb C1 (anti-BV17), 8F10 (anti-BV3), and others (16). 
PCR and Sequencing.  For typing of alleles of the BV3-RSS, PCR 
was performed with predetermined optimal amounts of genomic 
DNA, primers at 200 nM, 1.5 mM MgCI2, dNTPs at 0.5 mM 
in 0.05 ml of 10 mM Tris (pH 9 at 25~  50 mM KC1, 0.01% 
gelatin, and 0.1% Triton X-100 (36 cycles at 94~  for I min, 51~ 
for 1 min,  72~  for 1.5 min, with a final cycle at 72~  for 10 
rain). The primers used were based on a sequence of the BV3 gene 
of the cosmid clone 46.1 (17). They were BV3-intron 5' CCTTGA- 
TGGCCTGTTTTTCAC 3' (sense) and BV3-3' of RSS 5' GTG- 
CCATCGGAGCCAGCAC 3' (antisense). These primers amplify 
a 431-bp fragment including the entire second BV3 exon and the 
RSS. The PCR product was then digested with PvulI to distin- 
guish between the two alleles. 
For sequencing of genomic BV3, overlapping PCR fragments 
were amplified  and cloned. The downstream fragment is described 
above and the upstream fragment (392 bp), including 209 bp of 
promoter region, the first BV3 exon, and most of the intron was 
amplified  with the following primers: 5'GCTGTGTCAACTCTT- 
TTCTA 3' (sense) and 5' TGAGAGACAGAAAGCAAGG  3' (anti- 
sense). 35 clones were sequenced  from the various members of the 
D family, usually with at least three replicates to recognize Taq 
errors. The Taq error rate was ,,~1/2,000 bp. 
Additional nucleotide sequences extending 5' and 3' of the BV3 
gene were determined by cycle sequencing on two cosmids, H46.1 
and HVB19.1 (17a). To test for polymorphism in these flanking 
regions, genomic DNA corresponding to 842 bp 5' of the ATG 
codon of the BV3 gene and 100 bp 3' of the RSS heptamer were 
separately amplified  from 14 unrelated individuals.  PCR bands were 
separated on low melting agarose and directly sequenced (18) on 
both strands. 
Haflotyping.  Segregation ofallelic forms of TCRBV genes was 
followed in families. The allelic markers carried by each parental 
haplotype were determined and haplotypes were assigned to family 
members. In family D,  TCRBV alleles, including TCRBV6S1, 
TCRBV12S2, TCRBV12S3, TCRBV20,  and  TCRBC3',  were 
characterized by single stranded conformational polymorphism 
(SSCP) as described (19). In other families,  RFLPs of  TCRBVSS2/ 
BamHI, TCRBV7S2/BamHI, TCRBC/BgllI, TCRBC/KpnI, and 
microsatellites within the intron of TCRBV6S7 and TCRBV6S1 
(20) were used to determine haplotypes. 
HLA Typing.  HLA typing was performed according to previ- 
ously defined methods (21) and by PCR (22). Part of the typing 
for families  23, 98, and 110 was kindly provided  by Dr. R. Spielman 
(University of Pennsylvania, Philadelphia, PA). 
Results and Discussion 
While screening normal donors for TCRBV expression 
with various specific mAb, we observed several donors with 
low percentages ofBV3 T cells per total CD3-positive T cells. 
The family of one such individual (family D, Fig. 1) was tested 
for BV3 expression,  demonstrating that only the blood of 
the mother (M) and one sibling ($4) contained about 4% 
BV3 T  cells, whereas that of the father (P) and $1-$3 con- 
tained <0.6% BV3 T cells (Fig.  1). By contrast, BV17 (and 
11 other Vfl tested) were expressed at similar levels in all family 
members (Fig. 1). These results are consistent with prior work 
by Malhotra et al. (6) in which PCR was used to assay BV3 
expression  in family studies. 
Four families were analyzed (Table 1). In each family BV3 
expression  correlated exactly with TCRB haplotypes. The 
maternal "c" haplotype in family D (M, $4), and the paternal 
"a" haplotype in family 98 (98.1 P, 98.3), both segregate with 
high BV3 expression.  By contrast, BV3 expression does not 
segregate with MHC haplotypes in family D. These data in- 
dicate that a gene within the TCRB locus is controlling the 
frequency of BV3-positive  cells. 
Expression of BV3 was never totally absent since brightly 
stained cells could always be observed even in donors with 
only 0.3% positive cells. Moreover,  similar results were ob- 
tained with another BV3-specific mAb, 5E4 (data not shown). 
Since BV3-expressing  cells were apparently present, even in 
individuals with very low percentages  of BV3 cells, it was 
important to demonstrate the presence of a normal BV3 gene 
in the various members of family D.  The initial approach 
was to done and sequence genomic BV3 from each family 
member. PCR-amplified DNA was subcloned into a TA over- 
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Figure 1.  Staining  for BV3 and BV17 in family  D. 
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Correlations with  TCR  Haplotypes 
BV3-RSS  TCRB  MHC 
Family  PvulI  haplotype  haplotype  BV3 
% 
D-P  1/1  a/b  a/b  0.6 
D-M  1/2  c/d  c/d  3.7 
D-S1  1/1  a/d  a/d  0.3 
D-S2  1/1  a/d  a/c  0.4 
D-S3  1/1  a/d  a/c  0.3 
D-S4  1/2  a/c  a/c  4.2 
98.1  P  1/2  a/b  a/b  3.9 
98.2  M  1/1  c/d  c/d  0.7 
98.3  1/2  a/c  b/c  5.5 
98.4  1/1  b/d  a/c  1.3 
98.5  1/1  b/c  b/c  0.5 
98.6  1/1  b/c  b/c  0.6 
98.7  1/1  b/c  b/d  1.1 
110.1 P  2/2  a/b  a/b  7.1 
110.2 M  2/2  c/d  c/d  7.4 
110.3  2/2  a/d  b/c  8.7 
110.5  2/2  b/d  b/d  9.6 
110.6  2/2  a/c  b/d  6.5 
110.7  2/2  a/d  b/c  7.3 
23.1 P  1/1  a/b  a/b  1.0 
23.2 M  2/2  c/d  c/d  9.1 
23.2  1/2  b/d  b/d  4.7 
23.4  1/2  b/d  a/c  4.0 
23.5  1/2  b/c  a/c  5.2 
23.6  1/2  a/d  b/d  4.5 
CysAlaSerSerLeu  7met  9mot 
allele  1  TGTGCCAGCAGTTTATGCACAGCGCAGCACAGCCGCATCCTCTCTGCACAAAA~GAGCGGAC  739 
allele  2  .................................  T  ............................ 
Pvu  II  CAGCTG 
7met  repeat  CACAGCY 
Figure 2.  Sequences  of the BV3-RSS  demonstrating  the difference  be- 
tween two alleles.  The nucleotide  numbering  is based  on 903 bp of  genomic 
sequence data available from EMBL/GenBank/DDBJ under accession 
number U08314. 
hang vector and several subclones (total 35) were sequenced 
from each individual of family D. All clones from P, $1, $2, 
and $3 yielded the same sequence (allele  1), but clones from 
M  and $4 yielded two sequences,  allele  1 and allele 2 (Fig. 
2).  For instance,  three clones represented allele  1 and four 
clones represent allele 2 for DNA derived from M. The two 
alleles of BV3 differed by a single base pair mutation in the 
23-bp spacer  region of the P,  SS downstream of BV3 (Fig. 
2).  A  total of 800 bp of sequence, including 209 bp from 
the promoter, both BV3 exons, the intron, and 96 bp of 3'UT, 
were otherwise identical in the various members of family 
D. Thus, all members of  family D possess an apparently normal 
BV3 gene. 
The mutation in the BV3-RSS results in a PvulI restric- 
tion enzyme site specific for allele 2, CAGCTG (Fig. 2). This 
allowed us to determine genotypes at this site and test for 
correlation with percentages of BV3-expressing T cells in the 
blood. Fig.  3 shows PvulI digests of PCR-amplified DNA 
using the primers flanking the BV3 gene with its RSS. PvulI 
cleaves the 431-bp PCR product from allele 2 into 352- and 
79-bp fragments. The presence of allele 2 correlates with ex- 
pression of larger percentages of BV3 cells in family D  (Fig. 
3) and in the other families (Table  1). In family 23, for ex- 
ample, the father is homozygous 1/1 (1.3% BV3 cells),  the 
mother is homozygous 2/2 (8.8%  BV3 cells),  and all sib- 
lings are heterozygous and express intermediate percentages 
of BV3  cells  (3.8-4.9%).  In  family  110, all  members  are 
homozygous 2/2 and have similar high percentages of BV3 
cells. 
These data confirm that a gene within the TCRB locus 
BV3 percentages are per total CD3+CD4  § cells except for family  D 
where the results are expressed  per total CD3 § cells. The HLA haplo- 
types were: 
Family D 
(a) A32-B62-Cw3-DRBl*  1301 
(b) A2-Bx-CwS-DRBI*  1301 
(c) A24-B7-Cw7-DRBl*0401 
(d) A1-B8-CwT-DRBI*  1302 
Family 23 
A24-B35-DR1 
A24-B39-DR8 
A1-B8-DP,7 
A2-B44-DP,4 
Family 110 
(a) A2-B40-DR4 
(b) A29-B12-DR7 
(c) A3-B7-DR1 
(d) A3-DR6 
Family 98 
A1-B17-DR7 
A2-B27-DR1 
Aw23-B12-DR5 
A1-B18-DR5 
Figure 3.  PvulI  digest of PCR amplified BV3-RSS from family D 
showing correlation  with percentage  of BV3 cells  in the blood. The lane 
marked with (*) is an undigested control. The lesser relative intensity 
of the lower band is likely  due to incomplete  PvulI digestion. 
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Figure  4.  Correlation between percentage of BV3-positive T  cells and 
BV3-RSS genotype in unrelated individuals. Both BV3- and BV17-positive 
cells  were  counted  as  a  percentage  of  either  all  CD3 +  cells  or  of 
CD3 + CD4 + cells. The means of BV3 percentages (per total CD3 or per 
total  CD3§  +)  in  the  three  genotype  groups  were  significantly 
different from one another (p <0.0001) by one-way analysis. 
is responsible  for the variable frequency  of BV3-expressing 
T cells, but do not distinguish  between several possibilities: 
(a) a mutation in the promoter of the BV3 gene might result 
in deficient BV3-DJ recombination, since recombination is 
dependent on transcriptional activity in the recombining locus 
(23); (b) a large insertion/deletion polymorphism near the 
BV3 gene or a structural defect elsewhere in the TCRB locus 
may affect BV3-DJ recombination by an unknown mecha- 
nism;  and (c) decreased recombination frequency of allele 1 
may be due to the point mutation in the spacer region of 
the BV3-R.SS. 
To rule out large insertion/deletion polymorphisms, we 
screened genomic DNA from the parents of family D by hy- 
bridization using two cosmid clones as probes (17). The cosmid 
clones both contain the BV3 gene segment and span in excess 
of 50 kb of genomic DNA including  sequences both up- and 
downstream of BV3. On Southern blots using five different 
restriction enzymes, both probes failed to uncover any large 
insertion/deletion variants (data not shown).  Moreover, se- 
quencing 842 bp 5' of the ATG codon and 100 bp 3' of the 
heptamer  in 14 unrelated  individuals,  including  the parents 
of family D, revealed no further polymorphism suggesting 
that  the promoter region of BV3 was not polymorphic. 
Unrelated  individuals  have a large  number  of different 
TCRB haplotypes (24, 25), even if they share allelic markers 
at a single site such as in the BV3-P,  SS. Thus, it was reasoned 
that if the BV3-P,  SS mutation was the direct cause for de- 
creased BV3 usage among T  cells, the correlation  between 
the PvulI-defined  alleles and percentages of BV3 cells should 
also hold true in unrelated  donors.  Fig. 4 shows a striking 
correlation between inheritance  of TCR BV3 alleles and the 
percentage  of BV3 cells. Generally, a genotype of 1/1 is as- 
sociated with low percentages  of BV3 cells (mean  1.2%  of 
CD3+CD4 + cells),  a genotype of 2/2 is  associated with 
high percentages of BV3 cells (mean 8.1%), and a heterozy- 
gous genotype of 1/2 is associated with intermediate percent- 
ages of BV3 cells (mean 4.7%).  Thus, the cumulative  data 
suggest that the single mutation in the BV3-RSS spacer affects 
V-DJ recombination for the BV3 gene  segment. 
The RSS mediating V-J recombination  in the mouse x and 
h loci are directly responsible for dramatic differences  in recom- 
bination frequency observed in plasmid recombination sub- 
strates (26). Previous data had suggested that a fixed length 
of 23 or 12 bp was required  for the RSS spacer region,  but 
that the nonconserved  spacer sequence itself was of no im- 
port. In contrast, mutations in the conserved heptamer  and 
nonamer reduce recombination frequency in artificial plasmid 
recombination  substrates  transfected  into pre-B  cells (27). 
However, recombination of genomic DNA in a physiologic 
in vivo setting cannot be assessed by these methods. 
It may be relevant that genomic DNA is often methylated 
at CpG islands and that methylation of plasmid recombina- 
tion substrates has been shown to inhibit recombination (28). 
Close scrutiny of the BV3-P, SS spacer of allele 1 reveals the 
sequence GCCGC, which may be methylated in vivo, whereas 
allele 2 contains  the sequence GCTGC at this site. Also of 
interest is the simple repeat of the heptamer observed in the 
BV3-RSS, as well as in many other RSS (29). Thus the se- 
quence  CACAGCGnnnCACAGCT  (allele 2)  may  allow 
functional binding of a required component of recombinase, 
whereas the sequence of allele I CACAGCGnnnCACAGCC 
does not. A future goal will be to determine the exact mech- 
anism by which the C/T substitution in the BV3 RSS affects 
recombination using plasmid  recombination substrates. 
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